Xponance Inc. Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Xponance Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,376 shares of the biopharmaceutical company’s stock after buying an additional 852 shares during the period. Xponance Inc.’s holdings in Regeneron Pharmaceuticals were worth $12,626,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. Ronald Blue Trust Inc. raised its position in Regeneron Pharmaceuticals by 18.8% during the 3rd quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 12 shares during the last quarter. Drive Wealth Management LLC raised its position in Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 12 shares during the last quarter. Cassia Capital Partners LLC raised its position in Regeneron Pharmaceuticals by 2.3% during the 3rd quarter. Cassia Capital Partners LLC now owns 589 shares of the biopharmaceutical company’s stock valued at $485,000 after purchasing an additional 13 shares during the last quarter. Sutton Wealth Advisors Inc. raised its position in shares of Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13 shares in the last quarter. Finally, Clearview Wealth Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 1.5% in the 4th quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock worth $751,000 after acquiring an additional 13 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,729 shares of company stock worth $13,124,641. Corporate insiders own 8.83% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of several research reports. Barclays increased their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 12th. Bank of America increased their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price for the company. Finally, Morgan Stanley increased their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $976.41.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded up $7.13 on Friday, reaching $901.12. 83,337 shares of the company’s stock traded hands, compared to its average volume of 489,474. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The stock has a 50-day simple moving average of $954.14 and a 200-day simple moving average of $890.55. The firm has a market cap of $98.91 billion, a PE ratio of 25.73, a P/E/G ratio of 2.60 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a 12 month low of $684.80 and a 12 month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.73 by $1.13. The firm had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business’s revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the firm posted $10.96 earnings per share. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.59 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.